In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.
Professor Joost Meijer discusses the complex etiology and diagnosis of BP

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP)

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Marta Ferrer discusses how chronic spontaneous urticaria profoundly impacts mental health and quality of life, with patients often undergoing extensive testing before receiving appropriate treatment.

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation